Towards achieving a vaccine-derived herd immunity threshold for COVID-19 in the U.S. - Gumel, Abba B.; Iboi, Enahoro A.; Ngonghala, Calistus N.; Ngwa, Gideon A. (medRxiv, 2021)
A novel coronavirus emerged in December of 2019 (COVID-19), causing a pandemic that continues to inflict unprecedented public health and economic burden in all nooks and corners of the world. Although the control of COVID-19 has largely focused on the use of basic public health measures (primarily based on using non-pharmaceutical interventions, such as quarantine, isolation, social-distancing, face mask usage and community lockdowns), three safe and highly-effective vaccines (by AstraZeneca Inc., Moderna Inc. and Pfizer Inc., with protective efficacy of 70%, 94.1% and 95%, respectively) have been approved for use in humans since December 2020. We present a new mathematical model for assessing the population-level impact of the three currently-available anti-COVID vaccines that are administered in humans. The model stratifies the total population into two subgroups, based on whether or not they habitually wear face mask in public. The resulting multigroup model, which takes the form of a deterministic system of nonlinear differential equations, is fitted and parametrized using COVID-19 cumulative mortality data for the third wave of the COVID-19 pandemic in the U.S. Conditions for the asymptotic stability of the associated disease-free equilibrium, as well as expression for the vaccine-derived herd immunity threshold, are rigorously derived. Numerical simulations of the model show that the size of the initial proportion of individuals in the masks-wearing group, together with positive change in behaviour from the non-masks wearing group (as well as those in masks-wearing group do not abandon their masks-wearing habit) play a crucial role in effectively curtailing the COVID-19 pandemic in the U.S. This study further shows that the prospect of achieving herd immunity (required for COVID-19 elimination) in the U.S., using any of the three currently-available vaccines, is quite promising. In particular, while the use of the AstraZeneca vaccine will lead to herd immunity in the U.S. if at least 80% of the populace is vaccinated, such herd immunity can be achieved using either the Moderna or Pfizer vaccine if about 60% of the U.S. population is vaccinated. Furthermore, the prospect of eliminating the pandemic in the US in the year 2021 is significantly enhanced if the vaccination program is complemented with nonpharmaceutical interventions at moderate increased levels of compliance (in relation to their baseline compliance). The study further suggests that, while the waning of natural and vaccine-derived immunity against COVID-19 induces only a marginal increase in the burden and projected time-to-elimination of the pandemic, adding the impacts of the therapeutic benefits of the vaccines into the model resulted in a dramatic reduction in the burden and time-to-elimination of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOne of the authors (ABG) acknowledge the support, in part, of the Simons Foundation (Award #585022) and the National Science Foundation (Award #1917512). CNN acknowledges the support of the Simons Foundation (Award #627346). GAN acknowledge the grants and support of the Cameroon Ministry of Higher Education, through the initiative for the modernisation of research in Higher Education.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this study is freely available from public sources identified in the manuscript.